These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 21279352

  • 1. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, Virgolini IJ.
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [Abstract] [Full Text] [Related]

  • 3. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [Abstract] [Full Text] [Related]

  • 4. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.
    Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, Gautsch K, Madleitner R, Nilica B, Sprinzl GM, Gastl G, Fraedrich G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):33-41. PubMed ID: 25134670
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Jan; 38(2):94-99. PubMed ID: 30630744
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
    Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, Malhotra A, Bal C.
    Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
    [Abstract] [Full Text] [Related]

  • 7. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification.
    Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):543. PubMed ID: 22237841
    [No Abstract] [Full Text] [Related]

  • 8. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
    Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC.
    Cochrane Database Syst Rev; 2015 Sep 29; 2015(9):CD009263. PubMed ID: 26417712
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb 29; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 10. The utility of 68Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience.
    Jaiswal SK, Sarathi V, Malhotra G, Hira P, Shah R, Patil VA, Dalvi A, Prakash G, Lila AR, Shah NS, Bandgar T.
    J Pediatr Endocrinol Metab; 2021 Jan 27; 34(1):109-119. PubMed ID: 33180042
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
    Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, Tan T, Rubello D, Al-Nahhas A.
    Mol Imaging Biol; 2011 Aug 27; 13(4):769-75. PubMed ID: 20700766
    [Abstract] [Full Text] [Related]

  • 12. A rare case of a 123I-MIBG SPECT/CT positive, but 68Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder.
    Kroiss AS, Uprimny C, Pichler R, Gasser RW, Virgolini IJ.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Aug 27; 37(5):315-317. PubMed ID: 30042056
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep 27; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
    Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, Dhillo W, Meeran K, Goldstone AP, Martin NM, Todd JF, Palazzo F, Tan T.
    Eur J Nucl Med Mol Imaging; 2012 Aug 27; 39(8):1266-70. PubMed ID: 22526961
    [Abstract] [Full Text] [Related]

  • 15. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.
    Gains JE, Aldridge MD, Mattoli MV, Bomanji JB, Biassoni L, Shankar A, Gaze MN.
    Nucl Med Commun; 2020 Nov 27; 41(11):1169-1177. PubMed ID: 32796449
    [Abstract] [Full Text] [Related]

  • 16. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb 27; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
    Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P.
    Nucl Med Commun; 2007 May 27; 28(5):359-63. PubMed ID: 17414885
    [Abstract] [Full Text] [Related]

  • 18. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP.
    J Clin Endocrinol Metab; 2009 Oct 27; 94(10):3922-30. PubMed ID: 19622618
    [Abstract] [Full Text] [Related]

  • 19. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K.
    J Natl Cancer Inst; 2012 May 02; 104(9):700-8. PubMed ID: 22517990
    [Abstract] [Full Text] [Related]

  • 20. 68Ga-DOTATATE PET in Restaging and Response to Therapy in Neuroblastoma: A Case Series and a Mini Review.
    AlSadi R, Maaz AUR, Bouhali O, Djekidel M.
    J Nucl Med Technol; 2023 Jun 02; 51(2):140-146. PubMed ID: 37192823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.